News
-
-
PRESS RELEASE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
NanoViricides, Inc. reports filing the Annual Report on Form 10-K with SEC showcasing achievements including Phase II trials for NV-387, an antiviral drug for Mpox and Ebola. Financials and milestones are detailed -
-
-
-
-
-
-
-